Evidence map›Paper›PMID 30559759›Full record

ArticleFrontiers in genetics2018

Persistence of Epigenomic Effects After Recovery From Repeated Treatment With Two Nephrocarcinogens.

Alice Limonciel, Simone G van Breda, Xiaoqi Jiang, Gregory D Tredwell, Anja Wilmes, Lydia Aschauer, Alexandros P Siskos, Agapios Sachinidis, Hector C Keun, Annette Kopp-Schneider and 3 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in genetics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 5 countries.

Alice LimoncielDivision of Molecular and Computational Toxicology, Amsterdam Institute for Molecules, Medicines and Systems, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.
Simone G van BredaDepartment of Toxicogenomics, GROW-School for Oncology and Development Biology, Maastricht University Medical Center, Maastricht, Netherlands.
Xiaoqi JiangDivision of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Gregory D TredwellDivision of Cancer, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, Hammersmith Hospital, London, United Kingdom.
Anja WilmesDivision of Molecular and Computational Toxicology, Amsterdam Institute for Molecules, Medicines and Systems, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.
Lydia AschauerDivision of Physiology, Department of Physiology and Medical Physics, Medical University of Innsbruck, Innsbruck, Austria.
Alexandros P SiskosDivision of Cancer, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, Hammersmith Hospital, London, United Kingdom.
Agapios SachinidisInstitute of Neurophysiology and Center for Molecular Medicine Cologne (CMMC), University of Cologne (UKK), Cologne, Germany.
Hector C KeunDivision of Cancer, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, Hammersmith Hospital, London, United Kingdom.
Annette Kopp-SchneiderDivision of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Theo M de KokDepartment of Toxicogenomics, GROW-School for Oncology and Development Biology, Maastricht University Medical Center, Maastricht, Netherlands.
Jos C S KleinjansDepartment of Toxicogenomics, GROW-School for Oncology and Development Biology, Maastricht University Medical Center, Maastricht, Netherlands.
Paul JenningsDivision of Molecular and Computational Toxicology, Amsterdam Institute for Molecules, Medicines and Systems, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.
Maastricht University · NLHeidelberg University · DEImperial College London · GBInnsbruck Medical University · ATUniversität Innsbruck · ATHammersmith Hospital · GBUniversity of Cologne · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The discovery of the epigenetic regulation of transcription has provided a new source of mechanistic understanding to long lasting effects of chemicals. However, this information is still seldom exploited in a toxicological context and studies of chemical effect after washout remain rare. Here we studied the effects of two nephrocarcinogens on the human proximal tubule cell line RPTEC/TERT1 using high-content mRNA microarrays coupled with miRNA, histone acetylation (HA) and DNA methylation (DM) arrays and metabolomics during a 5-day repeat-dose exposure and 3 days after washout. The mycotoxin ochratoxin A (OTA) was chosen as a model compound for its known impact on HA and DM. The foremost effect observed was the modulation of thousands of mRNAs and histones by OTA during and after exposure. In comparison, the oxidant potassium bromate (KBrO

Indexed as

epigenomicsmetabolomicsnephrotoxicityochratoxin Apersistencepotassium bromaterecoverystress responses

Identifiers

PMID30559759
PMCPMC6286959
OpenAlexW2902674496

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.